Blijvend voordeel venetoclax plus rituximab bij recidiverend/refractair CLL

Bronnen:
Seymour JF, Kipps TJ, Eichhorst B, et al. MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting and Exposition 2018, abstract 184.